Literature DB >> 15728705

No increase of apoptosis in regressing mouse liver after withdrawal of growth stimuli or food restriction.

Wilfried Bursch1, Ute Wastl, Karin Hufnagl, Rolf Schulte-Hermann.   

Abstract

In short-term in vivo experiments, liver growth and regression in mice with high (C3H/He), intermediate (B6C3F1) or low (C57BL/6J) susceptibility to hepatocarcinogenesis was compared. Liver growth was induced by dietary administration of phenobarbital (PB; 750 ppm) or nafenopin (NAF; 500 ppm). PB or NAF treatment for 7 days produced moderate increases of liver DNA (15% or 25-28%, respectively) along with pronounced hypertrophy. Liver growth was strongest in C3H/He mice. Cessation of PB or NAF treatment led to a rapid regression of liver hypertrophy. However, the enhanced hepatic DNA content persisted for at least 2 weeks in all mouse strains. Apoptosis was not increased at any time after cessation of treatment in all strains. Food restriction to 60% of the ad libitum intake did not amplify either regression of liver hyperplasia or the occurrence of apoptosis. No strain difference in the occurrence of apoptosis was detected. Mouse hepatocytes in liver regressing after mitogen withdrawal do not enter apoptosis as readily as rat hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728705     DOI: 10.1093/toxsci/kfi128

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  1 in total

Review 1.  Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator.

Authors:  Clifford R Elcombe; Richard C Peffer; Douglas C Wolf; Jason Bailey; Remi Bars; David Bell; Russell C Cattley; Stephen S Ferguson; David Geter; Amber Goetz; Jay I Goodman; Susan Hester; Abigail Jacobs; Curtis J Omiecinski; Rita Schoeny; Wen Xie; Brian G Lake
Journal:  Crit Rev Toxicol       Date:  2013-11-04       Impact factor: 5.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.